Trial Designs For Non-Metastatic Prostate Cancer On Oncologics Advisory Committee Agenda
This article was originally published in The Pink Sheet Daily
Men who have no metastases yet their PSAs are climbing after androgen-depravation therapy need new treatment options, FDA maintains, while clinicians may argue what they need is better quality imaging.
You may also be interested in...
The launch of two drugs for metastatic prostate cancer this year – Dendreon Corp.'s Provenge (sipuleucel-T) and Sanofi-Aventis SA's Jevtana (cabazitaxel) – is shining a spotlight on an area of oncology that for many years was marked by a dearth of new treatment options.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.